- Home
- HRTX vs WHWK Comparison
HRTX vs WHWK Comparison
Compare HRTX & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRTX | WHWK |
|---|---|---|
| Founded | 1983 | 2007 |
| Country | United States | United States |
| Employees | N/A | 23 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.3M | 233.4M |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | HRTX | WHWK |
|---|---|---|
| Price | $0.43 | $3.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $4.50 | ★ $7.50 |
| AVG Volume (30 Days) | ★ 3.4M | 685.2K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $154,904,000.00 | N/A |
| Revenue This Year | $15.28 | N/A |
| Revenue Next Year | $20.29 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.36 | N/A |
| 52 Week Low | $0.38 | $1.57 |
| 52 Week High | $2.04 | $5.50 |
Technical Indicators
Market Signals| Indicator | HRTX | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 38.66 | 40.74 |
| Support Level | $0.38 | $3.24 |
| Resistance Level | $0.46 | $4.38 |
| Average True Range (ATR) | 0.03 | 0.31 |
| MACD | 0.02 | -0.04 |
| Stochastic Oscillator | 59.40 | 6.19 |
Price Performance
Historical ComparisonAbout HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.